Developer docs
API playgroundTry for free, no card

Search company profiles

DAAN Biotherapeutics

Full company profile

uuid000296d

Namestring
DAAN Biotherapeutics
Legal namestring
주식회사 다안바이오테라퓨틱스
Websiteurl
daanbiotpx.com
Company typeenum
Private
Founded yearint
2020
Descriptiontext

DAAN Biotherapeutics (주식회사 다안바이오테라퓨틱스) is a private, clinical-stage biotechnology company founded in 2020 in Seoul, South Korea, developing next-generation T-cell immunotherapies for solid tumors, with a primary focus on EGFR-mutant lung cancer that has developed resistance to existing targeted therapies. The company's pipeline is anchored by DN-101, a TCR-T cell therapy candidate planned for IND filing and global market entry by 2026, and is supported by three complementary proprietary technology platforms: a TCR-T cell therapy platform that targets intracellular tumor antigens presented by peptide-HLA complexes, expanding addressable targets beyond conventional surface antigens; TCR-mimic T-cell engagers that combine antibody druggability with TCR specificity for off-the-shelf delivery; and the TACTIC (Tumor tArgeting Conditionally acTIvated T-Cell engager) platform, which uses cleavable linkers to keep engagers inactive in normal tissue and selectively activate them within the tumor microenvironment. A fourth modality, the Probody bispecific antibody platform, targets CD3 and tumor-specific markers in solid tumors including colorectal, lung, and gastric cancers.

The company's business model centers on technology licensing and transfer, with revenue generated through exclusive and non-exclusive deals that monetize non-core assets while retaining rights to the core TCR-T and T-cell engager pipeline. Key agreements include an exclusive technology transfer to LigaChemBio for ADC development (signed February 2025), an exclusive technology transfer to GC Cell for CAR-T and CAR-NK applications (signed April 2025), and a strategic licensing arrangement with OmniAb for antibody discovery (signed June 2024). DAAN was founded by Professor Jo Byeong-cheol, head of the Lung Cancer Center at Yonsei Cancer Hospital and the principal investigator behind Yuhan Corporation's FDA-approved lung cancer drug Leclaza (lazertinib), and has secured two consecutive Korean National Drug Development Program selections (2024 for DN-101, 2025 for the Probody platform) plus approximately 23 billion KRW (~$17 million) in Series A funding in January 2024.

Short descriptiontext

DAAN Biotherapeutics is a Seoul-based, clinical-stage biotechnology company founded in 2020 that develops TCR-T cell therapies, TCR-mimic T-cell engagers, and conditionally activated T-cell engagers targeting EGFR-mutant lung cancer and other solid tumors, monetizing assets via technology licensing.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSeoul, South Korea
HQ citystring
Seoul
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
T-cell immunotherapy, cell therapy platforms, oncology biologics, antibody drug conjugates, cancer drug development
Industry2 codes
PRIMARYHLAAABAC
CAR-T & TCR-T Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Cancer Immunotherapy
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Licensing and Technology Transfer
TypeLicensing Royalties
Description

DAAN generates revenue through licensing out proprietary antibody sequences and technology to partner companies, including exclusive technology transfers for ADC development (LigaChemBio), CAR-T/CAR-NK applications (GC Cell), and antibody development (OmniAb).

daanbiotpx.com
2Drug Development and Commercialization
TypeOne Time License
Description

Pre-revenue clinical-stage biotech developing TCR-T cell therapy DN-101 and T-cell engagers targeting EGFR-mutant lung cancer and other solid tumors. Planning global market entry by 2026 for its core pipeline.

daanbiotpx.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

DAAN Biotherapeutics develops T-cell immunotherapies for cancer, anchored by lead drug candidate DN-101 (a TCR-T cell therapy targeting EGFR-mutant lung cancer resistant to existing treatments) and supported by three proprietary platforms: a TCR-T cell therapy platform, TCR-mimic T-cell engagers, and the TACTIC conditionally activated T-cell engager platform. The company licenses its antibody sequences and platform technologies to pharma partners while independently advancing its own pipeline toward IND filing and global commercialization.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Series A funding of 23 billion KRW raised in January 2024
+2 more records
Product overview1 text field

DAAN Biotherapeutics is a clinical-stage biopharmaceutical company pioneering next-generation T-cell immunotherapies to redefine cancer treatment. The company's integrated product portfolio centers on DN-101, its lead TCR-T cell therapy pipeline targeting EGFR mutant lung cancer, supported by three complementary technology platforms: the TCR-T Cell Therapy Platform for intracellular antigen recognition, the TCR-mimic T-cell Engagers for off-the-shelf immunotherapy, and the TACTIC (conditionally activated T-cell engager) platform and Probody Bispecific Antibody platform for tumor-selective activation. Together, these platforms address major challenges limiting current immunotherapies including tumor heterogeneity, off-tumor toxicity, insufficient tumor selectivity, and T-cell dysfunction within the tumor microenvironment.

Product and service5 records
1DN-101 TCR-T Cell Therapy
CategoryCancer cell therapy pipeline
Description

Lead clinical pipeline candidate: a TCR-T cell therapy targeting EGFR-mutant lung cancer resistant to existing treatments, designed for patients with limited therapeutic options on current targeted therapies and immunotherapies. Being advanced toward preclinical and clinical development with the goal of global market entry by 2026.

2TCR-T Cell Therapy Platform
CategoryImmunotherapy platform
Description

Platform technology that recognizes intracellular tumor-specific antigens presented by peptide–HLA complexes, enabling access to a broader target space beyond conventional surface antigens for solid tumor treatment. Licensable to partners and applied to DN-101 and other internal programs.

3TCR-mimic T-Cell Engager Platform
CategoryImmunotherapy platform
Description

Off-the-shelf immunotherapy approach combining the druggability of antibodies with the specificity of TCR biology to selectively target cancer-associated peptide–MHC complexes. Licensed to partners for CAR-T, CAR-NK, and ADC applications.

4TACTIC (Tumor tArgeting Conditionally acTIvated T-Cell engager) Platform
CategoryImmunotherapy platform
Description

Proprietary conditionally-activated T-cell engager technology using cleavable linkers that remain inactive in normal tissues and become selectively activated within the tumor microenvironment, minimizing systemic toxicity while maximizing anti-tumor activity. Applied to Probody bispecific antibody development.

5Probody Bispecific Antibody Platform
CategoryBispecific antibody platform
Description

Tumor-microenvironment-responsive bispecific antibody platform targeting CD3 on T lymphocytes and tumor-specific markers overexpressed in solid tumors such as colorectal, lung, and gastric cancers. Selected for the 2025 National Drug Development Program.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
1Triose (트리오어)
Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2025-11-17
Description

DAAN and Triose signed an MOU for collaboration in the ADC (Antibody-Drug Conjugate) field. The partnership covers antibody-based new drug technology exchange, ADC candidate substance discovery and evaluation, and future joint research and development expansion. The goal is to leverage DAAN's target discovery platform and antibody development technology combined with Triose's proprietary ADC platform for globally competitive ADC pipeline development.

medicaltimes.com
Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2025-08-04
Description

DAAN and ACROBiosystems signed an MOU for precision immunotherapy development. ACROBiosystems provides stable supply of high-performance bio-reagents, technology cooperation for immuno-oncology drug development, and joint research and data sharing. ACROBiosystems offers GMP-grade raw materials and QC solutions for cell and gene therapy CMC stages.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-04-21
Description

DAAN signed an exclusive technology transfer agreement with GC Cell for tumor antigen-specific antibody sequences to advance CAR-T and CAR-NK cell therapies. GC Cell validated the antibodies in CAR-T and CAR-NK formats, confirming strong efficacy and confirming DAAN's antibody engineering capabilities.

Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2024-10-10
Description

DAAN and Protina signed an MOU for research and development cooperation focused on TCR therapy development and optimization. Protina contributes its SPID (Single molecule Protein Interaction Detection) platform for ultra-high-speed analysis of protein interactions at the single-molecule level, which will be applied to optimize DAAN's TCR therapy candidates.

Strategic tierSupportingTypeTechnology or IntegrationAnnounced on2024-06-12
Description

DAAN entered a strategic licensing agreement with OmniAb for antibody treatment development. OmniAb, which possesses platform technology for human antibody-producing transgenic animals (mice, birds), shares its technology with DAAN to accelerate DAAN's antibody therapeutic development and strengthen its competitiveness in the global biopharmaceutical market.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-25
Description

DAAN transferred a tumor antigen-targeting antibody sequence to LigaChemBio for use in ADC (Antibody-Drug Conjugate) development. The antibody demonstrated strong anti-tumor activity in solid tumor models and showed competitive performance compared to global pharma ADCs. This was DAAN's first technology transfer, validated through approximately one year of MTA-based joint preclinical studies.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Immatics develops TCR-based immunotherapies and TCR-mimic (XEPURE) bispecifics targeting intracellular tumor antigens presented on HLA—the closest technological analogue to DAAN's TCR-T and TCR-mimic platforms, targeting solid tumors with similar modalities.

TypeDirect peer
Description

Adaptimmune is a clinical-stage TCR-T cell therapy company with FDA-approved Tecelra for synovial sarcoma, directly competing with DAAN in autologous TCR-T for solid tumors with a similar target-discovery approach.

TypeBroad incumbent
Description

Allogene is a leading allogeneic CAR-T company pursuing off-the-shelf cell therapy strategies; comparable to DAAN in modality category (engineered T-cell therapies) but broader in indication scope and at a later clinical stage.

TypeBroad incumbent
Description

Cellectis develops gene-edited allogeneic CAR-T cell therapies using TALEN technology, sharing DAAN's gene-engineering approach to T-cell biology but with a broader pipeline in hematologic malignancies.

TypeBroad incumbent
Description

Fate Therapeutics is a clinical-stage cell therapy company developing off-the-shelf iPSC-derived NK and T-cell therapies, comparable to DAAN's pursuit of off-the-shelf modalities through its TCR-mimic platform.

TypeDirect peer
Description

Poseida develops non-viral CAR-T and TCR-T cell therapies for solid and hematologic cancers, sharing DAAN's focus on engineered T-cell modalities and TCR-based targeting of solid tumor antigens.

TypeBroad incumbent
Description

2seventy bio is a cell therapy company with the approved BCMA-directed CAR-T Abecma; comparable to DAAN as a T-cell-redirecting therapy developer though focused on hematologic rather than solid tumors.

TypeRegional player
Description

JW Therapeutics is a China-based clinical-stage cell therapy company with an approved CAR-T (Carteyva), serving as the closest Asia-Pacific peer to DAAN in modality and stage, though currently focused on hematologic indications.

TypeBroad incumbent
Description

Genmab is a leading bispecific antibody developer (DuoBody platform) with multiple approved products; comparable to DAAN's Probody bispecific T-cell engager platform in targeting solid tumors via T-cell engagement, but at far greater scale and commercialization.

TypeBroad incumbent
Description

Crispr Therapeutics develops gene-edited cell therapies including allogeneic CAR-T products, comparable to DAAN in leveraging advanced cell engineering for next-generation T-cell therapies, though at a later clinical and commercialization stage.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors15 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

DAAN Biotherapeutics

Cancer Immunotherapydaanbiotpx.com

DAAN Biotherapeutics is a Seoul-based, clinical-stage biotechnology company founded in 2020 that develops TCR-T cell therapies, TCR-mimic T-cell engagers, and conditionally activated T-cell engagers targeting EGFR-mutant lung cancer and other solid tumors, monetizing assets via technology licensing.

What DAAN Biotherapeutics does

DAAN Biotherapeutics (주식회사 다안바이오테라퓨틱스) is a private, clinical-stage biotechnology company founded in 2020 in Seoul, South Korea, developing next-generation T-cell immunotherapies for solid tumors, with a primary focus on EGFR-mutant lung cancer that has developed resistance to existing targeted therapies. The company's pipeline is anchored by DN-101, a TCR-T cell therapy candidate planned for IND filing and global market entry by 2026, and is supported by three complementary proprietary technology platforms: a TCR-T cell therapy platform that targets intracellular tumor antigens presented by peptide-HLA complexes, expanding addressable targets beyond conventional surface antigens; TCR-mimic T-cell engagers that combine antibody druggability with TCR specificity for off-the-shelf delivery; and the TACTIC (Tumor tArgeting Conditionally acTIvated T-Cell engager) platform, which uses cleavable linkers to keep engagers inactive in normal tissue and selectively activate them within the tumor microenvironment. A fourth modality, the Probody bispecific antibody platform, targets CD3 and tumor-specific markers in solid tumors including colorectal, lung, and gastric cancers.

The company's business model centers on technology licensing and transfer, with revenue generated through exclusive and non-exclusive deals that monetize non-core assets while retaining rights to the core TCR-T and T-cell engager pipeline. Key agreements include an exclusive technology transfer to LigaChemBio for ADC development (signed February 2025), an exclusive technology transfer to GC Cell for CAR-T and CAR-NK applications (signed April 2025), and a strategic licensing arrangement with OmniAb for antibody discovery (signed June 2024). DAAN was founded by Professor Jo Byeong-cheol, head of the Lung Cancer Center at Yonsei Cancer Hospital and the principal investigator behind Yuhan Corporation's FDA-approved lung cancer drug Leclaza (lazertinib), and has secured two consecutive Korean National Drug Development Program selections (2024 for DN-101, 2025 for the Probody platform) plus approximately 23 billion KRW (~$17 million) in Series A funding in January 2024.

DAAN Biotherapeutics firmographics

Firmographics
Name
DAAN Biotherapeutics
Legal name
주식회사 다안바이오테라퓨틱스
Website
https://daanbiotpx.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
1–10 employees
Short description
DAAN Biotherapeutics is a Seoul-based, clinical-stage biotechnology company founded in 2020 that develops TCR-T cell therapies, TCR-mimic T-cell engagers, and conditionally activated T-cell engagers targeting EGFR-mutant lung cancer and other solid tumors, monetizing assets via technology licensing.
Ownership category
akta.pro rank

DAAN Biotherapeutics industry classification

Industry
Product category
Cancer Immunotherapy
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAABAC
CAR-T & TCR-T Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

Keywords

  • T-cell immunotherapy
  • Cell therapy platforms
  • Oncology biologics
  • Antibody drug conjugates
  • Cancer drug development

Where DAAN Biotherapeutics is headquartered

Location

Headquarters

HQ city
Seoul
HQ country
South Korea
HQ region
Asia

Offices1 record

Markets served

DAAN Biotherapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Licensing and Technology Transfer: DAAN generates revenue through licensing out proprietary antibody sequences and technology to partner companies, including exclusive technology transfers for ADC development (LigaChemBio), CAR-T/CAR-NK applications (GC Cell), and antibody development (OmniAb).
  2. Drug Development and Commercialization: Pre-revenue clinical-stage biotech developing TCR-T cell therapy DN-101 and T-cell engagers targeting EGFR-mutant lung cancer and other solid tumors. Planning global market entry by 2026 for its core pipeline.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

DAAN Biotherapeutics product offering

Product offering

Core offering

DAAN Biotherapeutics develops T-cell immunotherapies for cancer, anchored by lead drug candidate DN-101 (a TCR-T cell therapy targeting EGFR-mutant lung cancer resistant to existing treatments) and supported by three proprietary platforms: a TCR-T cell therapy platform, TCR-mimic T-cell engagers, and the TACTIC conditionally activated T-cell engager platform. The company licenses its antibody sequences and platform technologies to pharma partners while independently advancing its own pipeline toward IND filing and global commercialization.

Product overview

DAAN Biotherapeutics is a clinical-stage biopharmaceutical company pioneering next-generation T-cell immunotherapies to redefine cancer treatment. The company's integrated product portfolio centers on DN-101, its lead TCR-T cell therapy pipeline targeting EGFR mutant lung cancer, supported by three complementary technology platforms: the TCR-T Cell Therapy Platform for intracellular antigen recognition, the TCR-mimic T-cell Engagers for off-the-shelf immunotherapy, and the TACTIC (conditionally activated T-cell engager) platform and Probody Bispecific Antibody platform for tumor-selective activation. Together, these platforms address major challenges limiting current immunotherapies including tumor heterogeneity, off-tumor toxicity, insufficient tumor selectivity, and T-cell dysfunction within the tumor microenvironment.

Differentiator

Problem solved

Functional benefit

Products and services

  • DN-101 TCR-T Cell Therapy Lead clinical pipeline candidate: a TCR-T cell therapy targeting EGFR-mutant lung cancer resistant to existing treatments, designed for patients with limited therapeutic options on current targeted therapies and immunotherapies. Being advanced toward preclinical and clinical development with the goal of global market entry by 2026.
  • TCR-T Cell Therapy Platform Platform technology that recognizes intracellular tumor-specific antigens presented by peptide–HLA complexes, enabling access to a broader target space beyond conventional surface antigens for solid tumor treatment. Licensable to partners and applied to DN-101 and other internal programs.
  • TCR-mimic T-Cell Engager Platform Off-the-shelf immunotherapy approach combining the druggability of antibodies with the specificity of TCR biology to selectively target cancer-associated peptide–MHC complexes. Licensed to partners for CAR-T, CAR-NK, and ADC applications.
  • TACTIC (Tumor tArgeting Conditionally acTIvated T-Cell engager) Platform Proprietary conditionally-activated T-cell engager technology using cleavable linkers that remain inactive in normal tissues and become selectively activated within the tumor microenvironment, minimizing systemic toxicity while maximizing anti-tumor activity. Applied to Probody bispecific antibody development.
  • Probody Bispecific Antibody Platform Tumor-microenvironment-responsive bispecific antibody platform targeting CD3 on T lymphocytes and tumor-specific markers overexpressed in solid tumors such as colorectal, lung, and gastric cancers. Selected for the 2025 National Drug Development Program.

Quantifiable outcome

  • Series A funding of 23 billion KRW raised in January 2024
  • +2 more outcomes

Companies that use DAAN Biotherapeutics

Customer profile

Segments2 records

Ideal customer profiles3 records

DAAN Biotherapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

DAAN Biotherapeutics partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered supporting and core.

  • Triose (트리오어)supportingStrategic or Co-development Partner · 17 November 2025DAAN and Triose signed an MOU for collaboration in the ADC (Antibody-Drug Conjugate) field. The partnership covers antibody-based new drug technology exchange, ADC candidate substance discovery and evaluation, and future joint research and development expansion. The goal is to leverage DAAN's target discovery platform and antibody development technology combined with Triose's proprietary ADC platform for globally competitive ADC pipeline development.
  • ACROBiosystems Group (아크로바이오시템즈)supportingStrategic or Co-development Partner · 4 August 2025DAAN and ACROBiosystems signed an MOU for precision immunotherapy development. ACROBiosystems provides stable supply of high-performance bio-reagents, technology cooperation for immuno-oncology drug development, and joint research and data sharing. ACROBiosystems offers GMP-grade raw materials and QC solutions for cell and gene therapy CMC stages.
  • GC Cell (지씨셀)coreStrategic or Co-development Partner · 21 April 2025DAAN signed an exclusive technology transfer agreement with GC Cell for tumor antigen-specific antibody sequences to advance CAR-T and CAR-NK cell therapies. GC Cell validated the antibodies in CAR-T and CAR-NK formats, confirming strong efficacy and confirming DAAN's antibody engineering capabilities.
  • Protina (프로티나)supportingStrategic or Co-development Partner · 10 October 2024DAAN and Protina signed an MOU for research and development cooperation focused on TCR therapy development and optimization. Protina contributes its SPID (Single molecule Protein Interaction Detection) platform for ultra-high-speed analysis of protein interactions at the single-molecule level, which will be applied to optimize DAAN's TCR therapy candidates.
  • OmniAbsupportingTechnology or Integration · 12 June 2024DAAN entered a strategic licensing agreement with OmniAb for antibody treatment development. OmniAb, which possesses platform technology for human antibody-producing transgenic animals (mice, birds), shares its technology with DAAN to accelerate DAAN's antibody therapeutic development and strengthen its competitiveness in the global biopharmaceutical market.
  • LigaChem Biosciences (리가켐바이오)coreStrategic or Co-development Partner · 25 January 2024DAAN transferred a tumor antigen-targeting antibody sequence to LigaChemBio for use in ADC (Antibody-Drug Conjugate) development. The antibody demonstrated strong anti-tumor activity in solid tumor models and showed competitive performance compared to global pharma ADCs. This was DAAN's first technology transfer, validated through approximately one year of MTA-based joint preclinical studies.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

DAAN Biotherapeutics competitors and assessment

Company assessment

Direct peers

  • Immatics: Immatics develops TCR-based immunotherapies and TCR-mimic (XEPURE) bispecifics targeting intracellular tumor antigens presented on HLA—the closest technological analogue to DAAN's TCR-T and TCR-mimic platforms, targeting solid tumors with similar modalities.
  • Adaptimmune Therapeutics: Adaptimmune is a clinical-stage TCR-T cell therapy company with FDA-approved Tecelra for synovial sarcoma, directly competing with DAAN in autologous TCR-T for solid tumors with a similar target-discovery approach.
  • Poseida Therapeutics: Poseida develops non-viral CAR-T and TCR-T cell therapies for solid and hematologic cancers, sharing DAAN's focus on engineered T-cell modalities and TCR-based targeting of solid tumor antigens.

Broad incumbents

  • Allogene Therapeutics: Allogene is a leading allogeneic CAR-T company pursuing off-the-shelf cell therapy strategies; comparable to DAAN in modality category (engineered T-cell therapies) but broader in indication scope and at a later clinical stage.
  • Cellectis: Cellectis develops gene-edited allogeneic CAR-T cell therapies using TALEN technology, sharing DAAN's gene-engineering approach to T-cell biology but with a broader pipeline in hematologic malignancies.
  • Fate Therapeutics: Fate Therapeutics is a clinical-stage cell therapy company developing off-the-shelf iPSC-derived NK and T-cell therapies, comparable to DAAN's pursuit of off-the-shelf modalities through its TCR-mimic platform.
  • 2seventy bio: 2seventy bio is a cell therapy company with the approved BCMA-directed CAR-T Abecma; comparable to DAAN as a T-cell-redirecting therapy developer though focused on hematologic rather than solid tumors.
  • Genmab: Genmab is a leading bispecific antibody developer (DuoBody platform) with multiple approved products; comparable to DAAN's Probody bispecific T-cell engager platform in targeting solid tumors via T-cell engagement, but at far greater scale and commercialization.
  • Crispr Therapeutics: Crispr Therapeutics develops gene-edited cell therapies including allogeneic CAR-T products, comparable to DAAN in leveraging advanced cell engineering for next-generation T-cell therapies, though at a later clinical and commercialization stage.

Regional players

  • JW Therapeutics: JW Therapeutics is a China-based clinical-stage cell therapy company with an approved CAR-T (Carteyva), serving as the closest Asia-Pacific peer to DAAN in modality and stage, though currently focused on hematologic indications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

DAAN Biotherapeutics compliance and trust

Trust signal

Compliance2 records

DAAN Biotherapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

DAAN Biotherapeutics leadership team

Management profile

Number of profiles

Profiles1 record

DAAN Biotherapeutics funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

DAAN Biotherapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DAAN Biotherapeutics

What does DAAN Biotherapeutics do?

DAAN Biotherapeutics develops T-cell immunotherapies for cancer, anchored by lead drug candidate DN-101 (a TCR-T cell therapy targeting EGFR-mutant lung cancer resistant to existing treatments) and supported by three proprietary platforms: a TCR-T cell therapy platform, TCR-mimic T-cell engagers, and the TACTIC conditionally activated T-cell engager platform. The company licenses its antibody sequences and platform technologies to pharma partners while independently advancing its own pipeline toward IND filing and global commercialization.

Is DAAN Biotherapeutics a public or private company?

DAAN Biotherapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was DAAN Biotherapeutics founded?

DAAN Biotherapeutics was founded in 2020. It employs 1 to 10 people.

Where is DAAN Biotherapeutics based?

DAAN Biotherapeutics is headquartered in Seoul, South Korea, in the Asia region.

How does DAAN Biotherapeutics make money?

Two revenue lines are on record. Licensing and Technology Transfer is the primary driver. The others are drug Development and Commercialization.

Who are DAAN Biotherapeutics's main competitors?

Direct peers on record are Immatics, Adaptimmune Therapeutics and Poseida Therapeutics. Broad incumbents are Allogene Therapeutics, Cellectis, Fate Therapeutics, 2seventy bio, Genmab and Crispr Therapeutics. JW Therapeutics is listed as a regional player.

Does DAAN Biotherapeutics have an API?

No public API is recorded for DAAN Biotherapeutics.

What industry is DAAN Biotherapeutics in?

DAAN Biotherapeutics's product category is Cancer Immunotherapy. Its primary akta.pro industry code is HLAAABAC, CAR-T & TCR-T Therapies, with a secondary code of HLAAABAL, Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
NatureKDDF: advancing Korea’s oncology sector globallyKDDF's $1.5B drug development program supports 496 projects, with 34 licensing deals and 7 FDA orphan drug designations as of October 2025. Three oncology companies—DAAN Biotherapeutics, ProEn Therapeutics, and Rznomics—are advancing TCR/TCE, ADC, and trans-splicing therapies, respectively. KDDF aims for four FDA/EMA-approved new drugs by 2030.Laotian TimesACROBiosystems and DAAN Biotherapeutics Sign Strategic MOU for the Development of Precision Immuno-Oncology TherapeuticsACROBiosystems and DAAN Biotherapeutics signed a strategic MOU to collaborate on precision immuno-oncology therapeutics, including bioreagent supply and joint research. DAAN's lead pipeline has completed preclinical development and is preparing for global clinical trials. The partnership aims to accelerate the development and commercialization of precision immunotherapies.YahooDAAN Biotherapeutics and GC Cell partner for CAR-T, CAR-NK therapiesDAAN Biotherapeutics granted GC Cell exclusive rights to use its antibody sequence in CAR-T and CAR-NK therapy research. The antibody targets a tumour antigen in colorectal and lung cancers, with upfront, milestone, and royalty payments. The partnership aims to commercialise cell therapies for solid tumours.ChosunbizLigaChem biosciences signs antibody tech deal with Da An biotherapeuticsLigaChem Biosciences signed an antibody technology introduction contract with Da An Biotherapeutics for developing antibody-drug conjugate (ADC) candidates. The deal involves Da An supplying antibodies that LigaChem will develop into ADCs targeting solid tumors like lung and colorectal cancer. LigaChem secured global rights for these ADCs.PR NewswireDAAN Biotherapeutics Signs Antibody Exclusive Licensing Agreement with LigaChem Biosciences for ADC (Antibody-Drug Conjugate) Therapeutic DevelopmentDAAN Biotherapeutics signed an exclusive licensing agreement with LigaChem Biosciences for a novel tumor-targeting antibody to advance ADC development. The partnership aims to develop ADCs for solid tumor patients, leveraging DAAN's antibody technology. DAAN also plans to expand into T-cell engagers using its TACTIC platform.ThebionewsLung cancer anti-cancer drug DaAn Biotherapeutics secures 23 billion won in Series A investment.DaAn Biotherapeutics has successfully raised 23 billion won in a Series A investment to develop an anti-cancer drug using T-cell receptors. The investment round included participation from multiple investment firms such as Solar Star Ventures and KB Investment. DaAn is focused on creating a treatment for EGFR mutant lung cancer, targeting patients who have become resistant to existing therapies.PR NewswireGenScript ProBio and DAAN Bio Therapeutics, Sign a Strategic Cooperation MOU for the Discovery and Development of Novel DrugsGenScript ProBio and DAAN Bio Therapeutics signed a strategic cooperation MOU on July 14, 2022, in Seoul, South Korea, to collaborate on cell and gene therapy (CGT) and biologics development. Under the agreement, both companies will cooperate across the full development pipeline, from discovery and manufacturing to clinical trials, with DAAN leveraging GenScript ProBio's one-stop CDMO service platform for GMP antibody production. The partnership aims to advance DAAN's bispecific antibody and cell therapy pipelines targeting unique cancer treatment markers identified through its proprietary single cell analysis platform.